论文部分内容阅读
用真核表达HPV16L1蛋白为抗原,酶联免疫吸附测定64例宫颈癌患者血清和阴道分泌物的相应抗体,并用型特异性聚合酶键反应检测宫颈癌组织HPV16L1基因。结果:宫颈癌组血清HPV16L1抗体阳性年64.1%,对照组20.8%;宫颈癌组阴道分泌物HPV16L1抗体阳性率64.1%,对照组25%;宫颈癌组HPV16L1基因检出率为42.2%,对照组10%。有显著差异(P<0.01)。结论:高危型HPV感染,宫颈癌患者有明显免疫反应,全身和局部无明显差异,真核表达HPV16L1蛋白可用于宫颈癌患者的抗体测定。
The eukaryotic expression of HPV16 L1 protein was used as antigen, and the corresponding antibody of serum and vaginal secretions of 64 patients with cervical cancer was detected by enzyme-linked immunosorbent assay. HPV16 L1 gene was detected by type-specific polymerase chain reaction in cervical cancer. Results: The positive rates of HPV16 L1 antibody in cervical cancer group were 64.1% in the positive group and 20.8% in the control group. The positive rate of HPV16 L1 antibody in cervical cancer group was 64.1% and 25% in the control group. The positive rate of HPV16 L1 gene in cervical cancer group was 42 .2%, control group 10%. There was a significant difference (P <0.01). CONCLUSION: High-risk HPV infection and cervical cancer patients have obvious immune response with no significant difference between the whole body and the local area. Eukaryotic expression of HPV16 L1 protein can be used for the determination of antibody in cervical cancer patients.